Global Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Set for Strong Expansion, Reaching $90.76 Billion With 10.6% CAGR by 2030
Uncover key drivers, emerging technologies, and competitive movements shaping the pharmaceutical contract development and manufacturing organization (cdmo) for formulations market from 2026–2035 with trusted insights from The Business Research Company
Starting from its 2026 valuation, what market size is the Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market expected to reach by 2030?
The pharmaceutical contract development and manufacturing organization (cdmo) for formulations market has experienced considerable expansion in recent years. It is projected to increase from $54.73 billion in 2025 to $60.7 billion in 2026, at a compound annual growth rate (CAGR) of 10.9%. The historical growth of this market can be attributed to several factors, including the scarcity of specialized peptide API manufacturers, a dependence on in-house peptide production, the development of new peptide therapeutics pipelines, more stringent regulatory compliance requirements, and the adoption of basic chemical synthesis methods.
The pharmaceutical contract development and manufacturing organization (cdmo) for formulations market size is projected to experience substantial expansion in the coming years. By 2030, its value is anticipated to reach $90.76 billion, exhibiting a compound annual growth rate (CAGR) of 10.6%. This projected growth over the forecast period stems from various factors, including progress in custom peptide synthesis technologies, an increase in commercial-scale GMP manufacturing, greater outsourcing to CROs and SMEs, the evolution of lifecycle management and process optimization strategies, and a rising need for clinical and preclinical peptide API manufacturing. Key developments expected during this period involve an uptick in outsourcing peptide API production to contract manufacturers, an expansion in GMP-grade output for both clinical and commercial provisions, a growing requirement for bespoke peptide synthesis and purification offerings, the broadening of peptide therapeutics pipelines among pharmaceutical firms, and an emphasis on process optimization and lifecycle management for peptide APIs.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25876&type=smp
What Drivers Are Driving Adoption Within The Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market?
The pharmaceutical contract development and manufacturing organization (CDMO) for formulations market is projected to experience growth fueled by an increase in drug development and manufacturing activities. These activities signify the intensified efforts by pharmaceutical and biopharmaceutical companies to research, develop, and produce new drugs. The rise in drug development and manufacturing activities stems primarily from the global demand for novel and effective therapeutics, which drives companies to expand their development pipelines and accelerate manufacturing timelines. A pharmaceutical CDMO supports drug development by formulating and optimizing dosage forms, conducting stability testing, and ensuring regulatory compliance. It also manages scale-up and production, enabling quicker, cost-efficient product launches. For instance, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based trade association representing the pharmaceutical industry in Europe, total pharmaceutical production in Europe was recorded at $422,803 million (€390,000 million) in 2023, a rise from $393,857 million (€363,300 million) in 2022, as reported in June 2023. Consequently, the increasing drug development and manufacturing activities are propelling the expansion of the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market.
How Is The Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Organized Into Various Segments?
The pharmaceutical contract development and manufacturing organization (cdmo) for formulations market covered in this report is segmented –
1) By Dosage Form: Oral Solids, Oral Liquids, Injectables, Topicals, Inhalation Products, Transdermal And Patches, Other Dosage Forms
2) By Therapeutic Area: Oncology, Cardiology, Central Nervous System, Gastroenterology, Infectious Diseases, Endocrinology
3) By End-User: Pharmaceutical Companies, Biopharmaceutical Companies, Other End-Users
Subsegments:
1) By Oral Solids: Tablets, Capsules, Granules, Powders, Modified-Release Formulations
2) By Oral Liquids: Syrups, Suspensions, Solutions, Emulsions, Elixirs
3) By Injectables: Vials, Ampoules, Prefilled Syringes, Lyophilized Injections, Injectable Emulsions
4) By Topicals: Creams, Ointments, Gels, Lotions, Foams,
5) By Inhalation Products: Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs), Nebulizer Solutions, Nasal Sprays, Inhalation Capsules
6) By Transdermal And Patches: Matrix Patches, Reservoir Patches, Drug-In-Adhesive Patches, Microneedle Patches, Iontophoretic Patches
7) By Other Dosage Forms: Suppositories, Ophthalmic Preparations, Buccal Tablets, Sublingual Tablets, Implants
Which Trends Are Expected To Influence The Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market In The Upcoming Years?
Leading companies within the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market are dedicating efforts to developing advanced solutions, such as biologic formulation platforms, with the goal of enhancing drug stability and accelerating the time-to-market for complex biologic therapies. Biologic formulation platforms represent specialized systems engineered to establish stable and efficient formulations of biologic drugs, carefully adjusting factors like pH, excipients, and delivery methods to improve stability, bioavailability, and safety throughout the entire product lifecycle. As an illustration, in June 2025, WuXi Biologics, a China-based contract research, development, and manufacturing organization, introduced WuXiHigh 2.0, which is a next-generation high-concentration formulation platform. This cutting-edge platform allows for biologic formulations to achieve protein concentrations of up to 230 mg/mL, exceeding the current Food and Drug Administration-approved maximum of 200 mg/mL, while also decreasing viscosity by up to 90% through the use of proprietary excipient blends and high-throughput instrumentation. It effectively addresses critical hurdles in developing high-concentration biologics, including viscosity and aggregation, and is designed to boost injection efficiency, patient compliance, and manufacturing outcomes across both clinical and commercial stages.
Who Are The Core Companies Influencing Trends In The Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market?
Major companies operating in the pharmaceutical contract development and manufacturing organization (cdmo) for formulations market are Thermo Fisher Scientific Inc., Lonza Group, Catalent Inc., WuXi Biologics, Samsung Biologics, Recipharm AB, Siegfried Holding AG, Evonik Industries AG, Almac Group, Aenova Group, Piramal Pharma Limited, Cambrex, Jubilant Pharmova Limited, CordenPharma, Altasciences, Hovione, Aurigene Pharmaceutical Services Ltd., DPT Laboratories Ltd., CARBOGEN AMCIS, Biopharma Group, LGM Pharma, Aarti Pharmalabs Limited.
Access The Complete Report For Deeper Market Insights:
Which Regions Are Projected To Dominate The Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market In The Coming Years?
Asia-Pacific was the largest region in the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmaceutical contract development and manufacturing organization (cdmo) for formulations market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=25876&type=smp
Browse Through More Reports Similar to the Global Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market 2026, By The Business Research Company
Pharmaceutical Contract Developments And Manufacturing Organization Cmo Market Report 2026
Topical Drugs Contract Development And Manufacturing Organization Cdmo Market Report 2026
Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization Cdmo Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
